CR9989A - Composición farmacéutica que comprende al menos un medicamento contra el cáncer y al menos un polímero - Google Patents
Composición farmacéutica que comprende al menos un medicamento contra el cáncer y al menos un polímeroInfo
- Publication number
- CR9989A CR9989A CR9989A CR9989A CR9989A CR 9989 A CR9989 A CR 9989A CR 9989 A CR9989 A CR 9989A CR 9989 A CR9989 A CR 9989A CR 9989 A CR9989 A CR 9989A
- Authority
- CR
- Costa Rica
- Prior art keywords
- medicinal
- polymer
- pharmaceutical composition
- methods
- against cancer
- Prior art date
Links
- 206010028980 Neoplasm Diseases 0.000 title abstract 2
- 201000011510 cancer Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 229920000642 polymer Polymers 0.000 title 1
- 239000000203 mixture Substances 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 3
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 abstract 1
- 229930012538 Paclitaxel Natural products 0.000 abstract 1
- 229940123237 Taxane Drugs 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940041181 antineoplastic drug Drugs 0.000 abstract 1
- 238000002512 chemotherapy Methods 0.000 abstract 1
- 208000022605 chemotherapy-induced alopecia Diseases 0.000 abstract 1
- 229960003668 docetaxel Drugs 0.000 abstract 1
- 229940079593 drug Drugs 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 238000005194 fractionation Methods 0.000 abstract 1
- 238000004519 manufacturing process Methods 0.000 abstract 1
- 229960001592 paclitaxel Drugs 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5146—Organic macromolecular compounds; Dendrimers obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyamines, polyanhydrides
- A61K9/5153—Polyesters, e.g. poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/51—Nanocapsules; Nanoparticles
- A61K9/5107—Excipients; Inactive ingredients
- A61K9/513—Organic macromolecular compounds; Dendrimers
- A61K9/5169—Proteins, e.g. albumin, gelatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Optics & Photonics (AREA)
- Nanotechnology (AREA)
- Physics & Mathematics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IN1327MU2005 | 2005-10-21 | ||
| IN1081MU2006 | 2006-07-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR9989A true CR9989A (es) | 2008-07-18 |
Family
ID=38163340
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR9989A CR9989A (es) | 2005-10-21 | 2008-05-20 | Composición farmacéutica que comprende al menos un medicamento contra el cáncer y al menos un polímero |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20100166872A1 (https=) |
| EP (1) | EP1962906A4 (https=) |
| JP (1) | JP2009512682A (https=) |
| AR (1) | AR058130A1 (https=) |
| AU (1) | AU2006324872B2 (https=) |
| BR (1) | BRPI0617663A2 (https=) |
| CA (1) | CA2626016A1 (https=) |
| CR (1) | CR9989A (https=) |
| EA (1) | EA015781B1 (https=) |
| IL (1) | IL190882A0 (https=) |
| MA (1) | MA29946B1 (https=) |
| RS (1) | RS20080167A (https=) |
| WO (1) | WO2007069272A2 (https=) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009087678A2 (en) * | 2007-12-24 | 2009-07-16 | Sun Pharma Advanced Research Company Limited | Nanodispersion |
| US8865223B2 (en) | 2008-02-11 | 2014-10-21 | Technion Research And Development Foundation Ltd. | Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents |
| US8871276B2 (en) | 2008-02-11 | 2014-10-28 | Technion Research And Development Foundation Ltd. | Beta-casein assemblies for mucosal delivery of therapeutic bioactive agents |
| WO2009101614A1 (en) * | 2008-02-11 | 2009-08-20 | Technion Research & Development Foundation Ltd. | Casein particles encapsulating therapeutically active agents and uses thereof |
| US8865222B2 (en) | 2008-02-11 | 2014-10-21 | Technion Research And Development Foundation Ltd. | Beta-casein assemblies for enrichment of food and beverages and methods of preparation thereof |
| GB0818747D0 (en) | 2008-10-13 | 2008-11-19 | Univ Nottingham | Biocompatible responsive materials |
| EP2266546A1 (en) | 2009-06-08 | 2010-12-29 | Advancell Advanced in Vitro Cell Technologies,S.A. | Process for the preparation of colloidal systems for the delivery of active compounds |
| EP2442805A4 (en) | 2009-06-19 | 2012-11-21 | Sun Pharma Advanced Res Co Ltd | NANODISPERSION OF A MEDICINE AND METHOD FOR PREPARING THE SAME |
| WO2011017835A1 (en) * | 2009-08-11 | 2011-02-17 | Nanjing University | Preparation method of protein or peptide nanoparticles for in vivo drug delivery by unfolding and refolding |
| IN2012DN02576A (https=) * | 2009-09-21 | 2015-08-28 | Jw Pharmaceutical Corportion | |
| US10842770B2 (en) | 2010-05-03 | 2020-11-24 | Teikoku Pharma Usa, Inc. | Non-aqueous taxane pro-emulsion formulations and methods of making and using the same |
| CA2801309C (en) * | 2010-06-01 | 2018-07-17 | Geistlich Pharma Ag | Methods and compositions for oral pharmaceutical therapy |
| WO2012058462A2 (en) * | 2010-10-29 | 2012-05-03 | Isis Pharmaceuticals, Inc. | Combination therapy for the treatment of cancer |
| EP2645991B1 (en) | 2010-12-02 | 2020-02-12 | GreenMark Biomedical Inc. | Aptamer bioconjugate drug delivery device |
| KR20140022904A (ko) | 2011-04-20 | 2014-02-25 | 유니버시티 오브 시드니 | 치료방법 및 그에 사용가능한 제제 |
| DK2701684T3 (en) | 2011-04-28 | 2017-09-18 | Platform Brightworks Two Ltd | Improved parenteral formulations of lipophilic pharmaceuticals and methods for their preparation and use |
| WO2013124867A1 (en) * | 2012-02-21 | 2013-08-29 | Amrita Vishwa Vidyapeetham University | Polymer - polymer or polymer - protein core - shell nano medicine loaded with multiple drug molecules |
| JP6280546B2 (ja) | 2012-06-26 | 2018-02-14 | デル マー ファーマシューティカルズ | ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法 |
| JO3685B1 (ar) | 2012-10-01 | 2020-08-27 | Teikoku Pharma Usa Inc | صيغ التشتيت الجسيمي للتاكسين غير المائي وطرق استخدامها |
| US10143700B2 (en) | 2013-02-19 | 2018-12-04 | Amrita Vishwa Vidyapeetham | Nanoparticle formulations for delivering multiple therapeutic agents |
| KR20160061911A (ko) | 2013-04-08 | 2016-06-01 | 데니스 엠. 브라운 | 최적하 투여된 화학 화합물의 치료 효과 |
| RS60093B1 (sr) | 2013-09-16 | 2020-05-29 | Astrazeneca Ab | Terapeutske polimerne nanočestice i postupci njihove pripreme i primene |
| KR20150047336A (ko) | 2013-10-24 | 2015-05-04 | 삼성전자주식회사 | 나노입자, 이를 제조하는 방법, 및 이의 용도 |
| HUP1300646A2 (en) | 2013-11-12 | 2015-05-28 | Druggability Technologies Ip Holdco Jersey Ltd | Complexes of fulvestrant and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
| CN103739672B (zh) * | 2013-12-31 | 2015-06-10 | 威特曼生物科技（南京）有限公司 | 一种聚乙二醇修饰的抑制vegfr2酪氨酸激酶多肽及其应用 |
| RU2591819C2 (ru) * | 2014-03-03 | 2016-07-20 | Закрытое акционерное общество "СКАЙ ЛТД" | Способ получения фолликулярного белкового препарата и препарат, полученный данным способом |
| CN117899029A (zh) | 2015-02-01 | 2024-04-19 | 希洛斯医药品股份有限公司 | 用于在患者中口服施用的含有砷的高表面积冻干组合物 |
| EP3265063A4 (en) | 2015-03-03 | 2018-11-07 | Cureport, Inc. | Dual loaded liposomal pharmaceutical formulations |
| US9895313B2 (en) | 2015-03-03 | 2018-02-20 | Cureport, Inc. | Combination liposomal pharmaceutical formulations |
| CN106137969B (zh) | 2015-04-03 | 2020-05-15 | 四川科伦药物研究院有限公司 | 多西他赛白蛋白纳米粒药物组合物及其制备方法及应用 |
| IL285928B2 (en) | 2016-05-06 | 2025-06-01 | Eagle Pharmaceuticals Inc | Fulvestrant formulations and methods of their use |
| EP3615011A4 (en) * | 2017-04-24 | 2021-01-06 | ZY Therapeutics Inc. | PHARMACEUTICAL COMPOSITION FOR IN VIVO ADMINISTRATION, PROCESS FOR THE PREPARATION OF A PHARMACOLOGICALLY ACTIVE PRINCIPLE SENSITIVELY INSOLUBLE IN WATER |
| WO2019028457A2 (en) * | 2017-08-04 | 2019-02-07 | University Of Houston System | FORMULATION OF NANOSUSPENSION OF DIETHYLSTILBESTROL INJECTABLE |
| WO2019191456A1 (en) | 2018-03-28 | 2019-10-03 | Greenmark Biomedical Inc. | Phosphate crosslinked starch nanoparticle and dental treatments |
| AU2019312592B2 (en) | 2018-07-31 | 2025-06-26 | Microbion Corporation | Bismuth-thiol compositions and methods for treating wounds |
| WO2020028558A1 (en) | 2018-07-31 | 2020-02-06 | Microbion Corporation | Bismuth-thiol compositions and methods of use |
| FR3087650B1 (fr) * | 2018-10-31 | 2021-01-29 | Bio Even | Flavine adenine dinucleotide (fad) pour son utilisation pour la prevention et/ou le traitement de cancer |
| CN114767879A (zh) * | 2022-06-02 | 2022-07-22 | 平顶山学院 | 一种多西紫杉醇恶性肿瘤靶向微球及其制备方法与应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2634397B2 (fr) * | 1986-12-31 | 1991-04-19 | Centre Nat Rech Scient | Procede de preparation de systemes colloidaux dispersibles d'une proteine sous forme de nanoparticules |
| US5766635A (en) * | 1991-06-28 | 1998-06-16 | Rhone-Poulenc Rorer S.A. | Process for preparing nanoparticles |
| WO1994026254A1 (en) * | 1993-05-17 | 1994-11-24 | The Liposome Company, Inc. | Incorporation of taxol into liposomes and gels |
| PT1023050E (pt) * | 1997-06-27 | 2013-12-04 | Abraxis Bioscience Llc | Novas formulações de agentes farmacológicos, métodos para a sua preparação e métodos para a sua utilização |
| HK1045646A1 (zh) * | 1999-05-21 | 2002-12-06 | Abraxis Bioscience, Llc | 蛋白質穩定化的藥理學活性劑，其製備方法及其使用方法 |
| AU2458501A (en) * | 2000-01-05 | 2001-07-16 | Imarx Therapeutics, Inc. | Pharmaceutical formulations for the delivery of drugs having low aqueous solubility |
| ITMI20001107A1 (it) * | 2000-05-18 | 2001-11-18 | Acs Dobfar Spa | Metodo per il trattamento di tumori solici mediante microparticelle di albumina incorporanti paclitaxel |
| EP1585504A4 (en) * | 2002-11-06 | 2009-07-15 | Azaya Therapeutics Inc | Protein stabilized liposomal formulations of pharmaceutical active ingredients |
| KR20120068035A (ko) * | 2002-12-09 | 2012-06-26 | 아브락시스 바이오사이언스, 엘엘씨 | 약리학적 물질의 조성물 및 그 전달방법 |
-
2006
- 2006-10-19 BR BRPI0617663-1A patent/BRPI0617663A2/pt not_active IP Right Cessation
- 2006-10-19 AU AU2006324872A patent/AU2006324872B2/en not_active Expired - Fee Related
- 2006-10-19 WO PCT/IN2006/000427 patent/WO2007069272A2/en not_active Ceased
- 2006-10-19 US US12/083,594 patent/US20100166872A1/en not_active Abandoned
- 2006-10-19 RS RSP-2008/0167A patent/RS20080167A/sr unknown
- 2006-10-19 EA EA200801132A patent/EA015781B1/ru not_active IP Right Cessation
- 2006-10-19 JP JP2008536207A patent/JP2009512682A/ja active Pending
- 2006-10-19 EP EP06847315A patent/EP1962906A4/en not_active Withdrawn
- 2006-10-19 CA CA002626016A patent/CA2626016A1/en not_active Abandoned
- 2006-10-20 AR ARP060104602A patent/AR058130A1/es unknown
-
2008
- 2008-04-15 IL IL190882A patent/IL190882A0/en unknown
- 2008-05-15 MA MA30925A patent/MA29946B1/fr unknown
- 2008-05-20 CR CR9989A patent/CR9989A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| RS20080167A (sr) | 2009-07-15 |
| JP2009512682A (ja) | 2009-03-26 |
| CA2626016A1 (en) | 2007-06-21 |
| AU2006324872B2 (en) | 2012-03-08 |
| BRPI0617663A2 (pt) | 2011-08-02 |
| EA015781B1 (ru) | 2011-12-30 |
| EP1962906A4 (en) | 2009-11-18 |
| AR058130A1 (es) | 2008-01-23 |
| MA29946B1 (fr) | 2008-11-03 |
| WO2007069272A2 (en) | 2007-06-21 |
| US20100166872A1 (en) | 2010-07-01 |
| EA200801132A1 (ru) | 2009-02-27 |
| WO2007069272A3 (en) | 2007-08-23 |
| AU2006324872A1 (en) | 2007-06-21 |
| EP1962906A2 (en) | 2008-09-03 |
| IL190882A0 (en) | 2008-11-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR9989A (es) | Composición farmacéutica que comprende al menos un medicamento contra el cáncer y al menos un polímero | |
| BRPI0806863B8 (pt) | uso de um éster de forbol na preparação de um medicamento para prevenção ou tratamento de uma infecção por hiv | |
| MX383835B (es) | Uso de cannabidiol en el tratamiento del complejo de escleroris tuberosa. | |
| CO6670567A2 (es) | Métodos de tratamiento contra el cáncer pancreático | |
| BRPI0809164B8 (pt) | Composição para administração tópica e composição farmacêutica compreendendo a referida composição | |
| AR073123A1 (es) | Composicion farmaceutica que comprende un taxano sustancialmente amorfo para utilizarse en el tratamiento de la enfermedad neoplasica | |
| MX359413B (es) | Metodos de tratamiento de carcinoma hepatocelular. | |
| MX380318B (es) | Nanoparticula que comprende rapamicina y albumina como agente anticancer. | |
| BR112014011841A2 (pt) | material de entrega de fármacos hidrofóbicos, método para a produção do mesmo e métodos para a entrega de uma composição de entrega de fármacos | |
| CL2008002224A1 (es) | Composicion farmaceutica que comprende a) un compuesto seleccionado entre paclitaxel, docetaxel, ispinesib, tiazoloquinolina, entre otro, y b) compuestos inhibidores de aurora quinasa seleccionados entre derivados de imidazopirazina; uso de combinacion y de la composicion para tratar el cancer. | |
| MX2011011514A (es) | Formulaciones de canabidiol y metodos para utilizarlas. | |
| UY30215A1 (es) | Derivados de cromanol sustituidos, procedimientos para su preparacion, composiciones farmacéuticas que los contienen y aplicaciones | |
| CO6311008A2 (es) | Composicion farmaceutica que comprende un agente que activa las celulas t regulatorias cd4+cd25+ | |
| SV2010003451A (es) | Derivados de pirimidina trisustituida para el tratamiento de enfermedades proliferativas | |
| EP3501546A3 (de) | Cystein-wirkstoff konjugate und ihre verwendung | |
| MX2010005931A (es) | Profarmacos de tetrahidrocanabinol, composiciones que comprenden profarmacos de tetrahidrocanabinol y metodos para utilizar los mismos. | |
| GT200900175A (es) | Derivados de ester y amida de indazolilo para el tratamiento de enfermedades mediadas por un receptor de glucocorticoides | |
| BRPI0714553B8 (pt) | derivados de camptotecina, processo para preparação dos mesmos, composição farmacêutica e seu uso | |
| DOP2006000057A (es) | Composición farmaceútica para el tratamiento del cáncer | |
| CO6382089A2 (es) | Compuestos,composiciones y metodos para el tratamiento de enfermadades causadas por un b-amiloide y sinucleinopatias | |
| BR112012023407A2 (pt) | composição em pó farmacêutica para instalação, e, processo para a preparação da mesma. | |
| BRPI0908194B8 (pt) | Uso de uma anexina a5 recombinante, e stent de eluição de fármaco | |
| ECSP088408A (es) | Composiciones farmacéuticas que comprenden combinaciones de analgésicos y anticonvulsivantes para el tratamiento del dolor agudo y crónico | |
| BR112013002832A2 (pt) | composição compreendendo retinol, um precursor ou um produto de reação do mesmo e um extrato vegetal de pelo menos uma planta de camomila para o tratamento de câncer | |
| UY31143A1 (es) | Derivados de [1,10]-fenantrolina para el tratamiento de enfermedades neurodegenerativas o hematologicas |